Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $35.4 million.

  • Corvus Pharmaceuticals' Total Current Liabilities fell 82.60% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 82.60%. This contributed to the annual value of $35.4 million for FY2024, which is 415.39% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Total Current Liabilities of $35.4 million as of FY2024, which was up 415.39% from $6.9 million recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Total Current Liabilities peaked at $35.4 million during FY2024, and registered a low of $6.9 million during FY2023.
  • Over the past 3 years, Corvus Pharmaceuticals' median Total Current Liabilities value was $10.8 million (recorded in 2022), while the average stood at $17.7 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 36.11% in 2023, then skyrocketed by 415.39% in 2024.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Total Current Liabilities stood at $10.8 million in 2022, then plummeted by 36.11% to $6.9 million in 2023, then skyrocketed by 415.39% to $35.4 million in 2024.